Showcasing Safety, Pharmacokinetic & Efficacy Data in Phase 1b Trials in Humans & Phase 2 Trials in Canines for the Tau Aggregate Degrader ATB2005A
- Introducing the AUTOTAC platform and its mechanism-of-action
- Discussing ATB2005A as a first-in-class Tau aggregate degrader
- Revealing detailed clinical data on ATB2005A